Abstract 6171
Background
Clinical trials using immune checkpoint inhibitors (ICPIs) against immune inhibitory receptor ligand 1 (PD-L1) have failed to show clinical benefit for glioblastoma (GBM) patients. This is likely due to multiple factors, including but not limited to, the immunologically cold GBM microenvironment lacking effector immune cells. PD-L1 expression in tumour cells can be regulated by epidermal growth factor receptor/janus kinase 2 (EGFR/JAK2) signalling that might weaken the antitumor immune response by increasing PD-L1 level. Furthermore, EGFR is mutationally activated in approximately 50% of GBMs. Therefore, we analysed changes in EGFR and PD-L1 expression levels in the intraoperative specimens obtained from patients diagnosed with primary GBMs.
Methods
In total, 27 patients with newly diagnosed GBM underwent surgery and were investigated for mRNA and protein expression level either of Ki67, EGFR/EGFRvIII and PD-L1 by quantitative reverse transcription-PCR (qRT-PCR) or immunohistochemistry (IHC).
Results
EGFR overexpression (IHC H-score > 200 [0-300]) was detected in 8/27(30%) specimens as assessed by IHC, whereas 25/27 samples (93%) showed increased EGFR mRNA expression, suggesting a higher sensitivity of qRT-PCR analysis. Of the 25, 10 patients were harbouring EGFRvIII mutation. PD-L1 protein expression (2+ and 3+ staining in > 5% cells) was present in 16/27(60%) samples, of which concurrent elevation of PD-L1 and EGFR mRNA copy numbers was seen in 9/16 samples. In contrast, IHC revealed EGFR overexpression in only 2/16 PDL-1 positive patients. Ki67 staining revealed great variety in proliferation status of the GBMs, with a median Ki67 index of 30 (range 10-62).
Conclusions
Collectively, these results confirm that primary GBMs are characterised by a considerable heterogeneity of EGFR, EGFRvIII and PD-L1 expressions at both mRNA and protein levels. The PD-L1 mRNA expression was found to be associated with EGFR mRNA copy number only in small group of patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
NCNOPUS13#2017/25/B/NZ5/00039, KNW-1-108/N/8/O.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3993 - Prophylaxis with Lipegfilgrastim in patients with primary breast cancer receiving dose dense chemotherapy: results from the German NIS NADENS
Presenter: Marion Kiechle
Session: Poster Display session 1
Resources:
Abstract
3471 - Randomized phase 2 trial evaluating the safety of peripherally inserted central catheters vs implanted port catheters during adjuvant chemotherapy in early breast cancer patients.
Presenter: Florian Clatot
Session: Poster Display session 1
Resources:
Abstract
1327 - Simultaneous intravenous fluid infusion to prevent oxaliplatin infusion-related venous pain
Presenter: Stefan Van Ravensteijn
Session: Poster Display session 1
Resources:
Abstract
5004 - Clinical practice evaluation of opioids induced constipation management in cancer patients: The EIO-Praxis project.
Presenter: Enrique Aranda Aguilar
Session: Poster Display session 1
Resources:
Abstract
2222 - Analysis of the efficacy of naloxegol in a real-world 12 weeks of follow-up study, in patients with cancer and opioid-induced constipation with laxative-inadequate response.
Presenter: Manuel Cobo Dols
Session: Poster Display session 1
Resources:
Abstract
5556 - Consensus on strategies in the management of opioid-induced constipation in cancer patients
Presenter: Regina Girones Sarrio
Session: Poster Display session 1
Resources:
Abstract
3913 - Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial
Presenter: Yanni Lou
Session: Poster Display session 1
Resources:
Abstract
2208 - A prospective study about the complementary medicine among patients with cancers
Presenter: Wala Ben Kridis
Session: Poster Display session 1
Resources:
Abstract
1082 - Prevalence and management of Potentially Inappropriate Medication use and Potential Omissions in Medication in older cancer patients - the PIM POM study
Presenter: Fianne van Loveren
Session: Poster Display session 1
Resources:
Abstract
1701 - Immunogenicity and optimal timing of 13-valent pneumococcal conjugate vaccination during adjuvant chemotherapy in gastric and colorectal cancer : A randomized controlled trial
Presenter: Wonyoung Choi
Session: Poster Display session 1
Resources:
Abstract